High-Tech Biochemical to resume vitamin C API production
Shanghai. July 29. INTERFAX-CHINA - Mudanjiang High-Tech Biochemical Co. Ltd. will resume vitamin C active pharmaceutical ingredient (API) production in September this year after an 18-month hiatus, local media reported on July 29.
According to Mudanjiang News, High-Tech Biochemical has invested RMB 25 million ($3.66 million) to upgrade its vitamin C API production line, which now has an annual production capacity of 1,500 tons. The production line will be operational come September this year.
The company is also constructing a new RMB 51 million ($7.47 million) vitamin C API production line with an annual production capacity of 3,000 tons, which is expected to be operational by the end of this year, the report said.
"Prior to the production suspension in April last year, we mainly produced starch-derived products such as crystalline dextrose. We also produced vitamin C API, but it was not our core business. We only had an annual production capacity of 1,000 tons of vitamin C API," a High-Tech Biochemical employee, who preferred to remain anonymous, told Interfax on July 29.
According to the report, High-Tech Biochemical will soon start the construction of another new vitamin C API production line with an annual production capacity of 20,000 tons. It is scheduled to be operational by the end of 2010.